Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Bifidobacterium breve MAK40B22B

What does the research say about Bifidobacterium breve MAK40B22B?

2 health outcomes synthesised

Bifidobacterium breve MAK40B22B has been studied in 2 health outcome areas across 6 total clinical trials. The strongest evidence supports a moderate reduction in body fat mass based on 3 studies in pre-obese and overweight adults, though the evidence strength is rated as low overall. No consistent effective dose could be identified from the available research.

Strongest evidence Both researched outcomes have low evidence strength, so no outcome qualifies as high or moderate strength. The most supported finding is a moderate reduction in body fat mass: all 3 studies reported beneficial effects, with 2 of 3 reaching statistical significance. Effects were observed at 8–12 weeks in pre-obese and overweight adults.

Mixed or weaker evidence Improved cognitive function is supported by 3 studies in older adults with mild cognitive impairment or subjective memory complaints, all showing statistically significant benefits. However, effect sizes were mixed (small to large), with the largest gains seen in memory subscales. The evidence is considered low strength and preliminary due to the small number of studies.

Effective dose patterns Dosing information could not be reliably extracted from studies for either outcome, so no dose range can be recommended. This is a notable gap in translating the research into practical guidance.

Population insights Research is narrowly focused: cognitive studies only include older adults with suspected mild cognitive impairment, and body fat studies only include pre-obese or overweight adults. Generalization to healthy or younger populations is not supported by current evidence.

Notable caveats

  • Both evidence bases are small (3 studies each), making conclusions preliminary.
  • Publication bias is a concern — null studies are less likely to be published.
  • No effective dose can be identified from the available data.
  • Cognitive benefits may not apply to healthy older adults or other age groups.

Frequently asked

  • What is Bifidobacterium breve MAK40B22B good for according to research?
    Research suggests Bifidobacterium breve MAK40B22B may support improved cognitive function and reduced body fat mass. Both outcomes have low evidence strength, with each based on 3 studies.
  • What dose of Bifidobacterium breve MAK40B22B is typically used in studies?
    Dosing information was not consistently reported in the available studies, so no typical or effective dose range can be identified from the research.
  • Who benefits most from Bifidobacterium breve MAK40B22B?
    Cognitive benefits have been studied only in older adults with mild cognitive impairment or subjective memory complaints. Body fat reductions have been studied only in pre-obese or overweight adults.
  • Are there caveats or limitations in the research on Bifidobacterium breve MAK40B22B?
    The evidence is preliminary — each outcome is supported by only 3 studies. Publication bias is likely, and dosing data are missing. Results may not generalize to healthier or younger populations.
  • Does Bifidobacterium breve MAK40B22B help with improved cognitive function?
    Three studies in older adults with mild cognitive impairment reported statistically significant improvements, particularly in memory. However, effect sizes varied and evidence strength is low.
  • Does Bifidobacterium breve MAK40B22B help with reduced body fat mass?
    All 3 studies reported moderate reductions in body fat mass, with 2 showing statistically significant effects. The research is limited to pre-obese and overweight adults.

Most-studied combinations with Bifidobacterium breve MAK40B22B

most supplement research is combination research
Also studied with:Bifidobacterium breve VPro 52 (10)
Back to top